Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.43 |
| ▸ | METAP1 | P53582 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662289 | 0.84 | ALDH1A1 (0.43) | METAP2METAP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL808899 | 0.84 | ALDH1A1 (0.43) | METAP2METAP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL808800 | 0.81 | ALDH1A1 (0.41) | METAP2METAP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4341912 | 0.79 | ACP3 (0.47) | METAP2METAP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL808922 | 0.79 | ACP3 (0.47) | METAP2METAP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL27633084 | 0.79 | ALDH1A1 (0.39) | METAP2METAP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL808809 | 0.79 | ALDH1A1 (0.39) | METAP2METAP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL809175 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL809182 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL808811 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1593674-B1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7683215-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7671213-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| CN-101125833-A | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| US-7288674-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| CN-1771236-A | Optically active bisoxazoline compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | ACSL3, ADSL, SQLE | METAP2 4249/4885METAP1 3986/4885ALDH1A1 897/4885 |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | METAP2 4249/4885METAP1 3986/4885ALDH1A1 897/4885 |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | METAP2 4249/4885METAP1 3986/4885ALDH1A1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.